Follitrope (follitropin alfa) demonstrates its high efficacy in the cycles of controlled ovulation induction, which makes the drug attractive for widespread clinical use due to its relatively low cost. Objective: to evaluate the efficiency of using the gonadotropin Follitrope for ovarian stimulation in controlled ovarian induction protocols in patients with normogonadotropic anovulation. Subjects and methods. A comparative randomized investigation was conducted to study a Follitrope dosage regimen and to evaluate its efficiency in the cycles of controlled ovulation induction. A total of 24 cycles were performed in a group of 28- to 35-year-old patients (n=18) diagnosed with secondary infertility associated with normogonadotropin anovulation. Randomization was done according to the choice of a starting follitrope dose in a ratio of 3:2 — 75 IU (n=11): 150 IU (n=7). Ovulation was stimulated under ultrasound guidance. Results. In the subgroup that used a smaller follitrope dose (75 IU), only 3 patients were observed to have adequate follicular growth by day 6 after initiation of the protocol, which required that the dose be increased up to 150 IU; a positive response to therapy was seen in all cases in the subgroup of patients receiving a starting drug dose of 150 IU. On the day of administration of the ovulation trigger, there were an average of 2.2 (1—4) and 3.9 (1—7) follicles in the groups with the starting doses of 75 and 150 IU, respectively. All the patients reported good tolerance and no adverse reactions during their treatment. Mild ovarian hyperstimulation was recorded in one patient. The cases of pregnancy diagnosable by determining free β-subunit of chorionic gonadotropin in the cohort group, including repeated ovarian stimulation with artificial insemination in 6 patients, were 72.2% (13/18) and those of clinical pregnancy were 61.1% (11/18). Conclusion. The clinical efficacy of Follitrope along with its price characteristics enables it to occupy a certain niche in the respective segment of the pharmaceutical market. The authors declare no conflicts of interest.